STTK 8-K 2026-11-05
Shattuck Labs, Inc. (STTK) 8-K dated 2026-11-05 — accession 0001628280-26-070613.
Shattuck Labs, Inc. (STTK) is a biotechnology company listed on US.
STTK: Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent B…
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported STTK revenue for 2025-12-31 was $1.0M. Net income was -$48.8M. Revenue was down 82.5% from 2024-12-31 to 2025-12-31. STTK currently screens at market cap $351.2M.
Not investment advice. The STTK SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects to initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027.
Why it matters
- expects to initiate a Phase 1 healthy volunteer clinical trial of SL-846 and report initial data in 2027.